Literature DB >> 10858396

Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.

R A Stockley1, C O'Brien, A Pye, S L Hill.   

Abstract

STUDY
OBJECTIVES: To stratify COPD patients presenting with an acute exacerbation on the basis of sputum color and to relate this to the isolation and viable numbers of bacteria recovered on culture.
DESIGN: Open, longitudinal study of sputum characteristics and acute-phase proteins.
SETTING: Patients presenting to primary-care physicians in the United Kingdom. Patients were followed up as outpatients in specialist clinic. PATIENTS: One hundred twenty-one patients with acute exacerbations of COPD were assessed together with a single sputum sample on the day of presentation (89 of whom produced a satisfactory sputum sample for analysis). One hundred nine patients were assessed 2 months later when they had returned to their stable clinical state.
INTERVENTIONS: The expectoration of green, purulent sputum was taken as the primary indication for antibiotic therapy, whereas white or clear sputum was not considered representative of a bacterial episode and the need for antibiotic therapy.
RESULTS: A positive bacterial culture was obtained from 84% of patients sputum if it was purulent on presentation compared with only 38% if it was mucoid (p < 0.0001). When restudied in the stable clinical state, the incidence of a positive bacterial culture was similar for both groups (38% and 41%, respectively). C-reactive protein concentrations were significantly raised (p < 0.0001) if the sputum was purulent (median, 4.5 mg/L; interquartile range [IQR], 6. 2 to 35.8). In the stable clinical state, sputum color improved significantly in the group who presented with purulent sputum from a median color number of 4.0 (IQR, 4.0 to 5.0) to 3.0 (IQR, 2.0 to 4. 0; p < 0.0001), and this was associated with a fall in median C-reactive protein level to 2.7 mg/L (IQR, 1.0 to 6.6; p < 0.0001).
CONCLUSIONS: The presence of green (purulent) sputum was 94.4% sensitive and 77.0% specific for the yield of a high bacterial load and indicates a clear subset of patient episodes identified at presentation that is likely to benefit most from antibiotic therapy. All patients who produced white (mucoid) sputum during the acute exacerbation improved without antibiotic therapy, and sputum characteristics remained the same even when the patients had returned to their stable clinical state.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10858396     DOI: 10.1378/chest.117.6.1638

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  107 in total

Review 1.  Management of an acute exacerbation of copd: are we ignoring the evidence?

Authors:  M K Johnson; R D Stevenson
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

2.  [Antimicrobial treatment of patients with severe acute exacerbation of COPD].

Authors:  B Klapdor; S Ewig
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-03-22       Impact factor: 0.840

3.  Relevance of lower airway bacterial colonization, airway inflammation, and pulmonary function in the stable stage of chronic obstructive pulmonary disease.

Authors:  M Zhang; Q Li; X-Y Zhang; X Ding; D Zhu; X Zhou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-08-20       Impact factor: 3.267

Review 4.  COPD exacerbations.5: management.

Authors:  R Rodríguez-Roisin
Journal:  Thorax       Date:  2006-06       Impact factor: 9.139

5.  Intermediate care--Hospital-at-Home in chronic obstructive pulmonary disease: British Thoracic Society guideline.

Authors: 
Journal:  Thorax       Date:  2006-11-07       Impact factor: 9.139

Review 6.  COPD exacerbations . 2: aetiology.

Authors:  E Sapey; R A Stockley
Journal:  Thorax       Date:  2006-03       Impact factor: 9.139

7.  Management of chronic obstructive pulmonary disease exacerbations: how well are we doing?

Authors:  Nicholas T Vozoris
Journal:  Can Respir J       Date:  2013 May-Jun       Impact factor: 2.409

8. 

Authors:  María José Monedero Mira; Manuel Batalla Sales; Concepción García Domingo; María José Monedero Mira; Belén Persiva Saura; Gloria Rabanaque Mallen; Lledó Tárrega Porcar
Journal:  FMC       Date:  2016-04-26

9.  Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations.

Authors:  I S Patel; T A R Seemungal; M Wilks; S J Lloyd-Owen; G C Donaldson; J A Wedzicha
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

Review 10.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.